Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
Adalimumab (ADA) trough level and anti-ADA antibody (AAA) positivity influence mucosal healing and loss of response in patients with inflammatory bowel disease (IBD). In this study, we clarified the correlation between ADA monitoring, including non-trough level, and real-world IBD clinical outcomes....
Saved in:
Main Authors: | Masaichi Kato, Ken Sugimoto, Kentaro Ikeya, Ryosuke Takano, Ai Matsuura, Takahiro Miyazu, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroyuki Hanai |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7bcc3f90536f46b3bb7962457b2aa47e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
by: Natsuki Ishida, et al.
Published: (2021) -
C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
by: Natsuki Ishida, et al.
Published: (2021) -
Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
by: Satoshi Tamura, et al.
Published: (2021) -
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
by: Satoshi Tamura, et al.
Published: (2020) -
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
by: Linda Cingolani, et al.
Published: (2021)